QUILT-3.055: what clinicians are saying
nogapendekin alfa inbakicept (N-803) plus pembrolizumab; nogapendekin alfa inbakicept (N-803) plus pembrolizumab plus PD-L1 t-haNK; nogapendekin alfa inbakicept (N-803) plus pembrolizumab plus docetaxel in cancer previously treated with immune checkpoint inhibitors · NCT03228667 ↗ · Phase 2 · ImmunityBio, Inc.
For QUILT-3.055, a hematology-oncology physician who describes presenting the update and helping develop the approach interprets responses as a signal of renewed checkpoint activity, but another physician wants randomized long-term survival and patient-centered evidence. A physician described in the sources as reporting their own results considers survival observations sufficient for faster access. Anktiva’s contribution beyond continued checkpoint inhibition remains disputed; the ALC–survival association does not prove that lymphocyte restoration causes benefit.
Created with AI · how we check it
- edition 1
- commentary checked Nov 20, 2026
- 91 verified statements
This edition $750, with MCP access for your AI agent. Get this report
10 findings, and what sits behind each
01. Checkpoint rescue: where clinicians split on readiness for routine use
4 of the report's 5 cited clinicians · 11 statements from 4 speakers in 2 sources, all podcasts or videos · 7 passages
Limitations recorded: 2.
Draws on: Population and setting, Secondary endpoints, Primary endpoint: ORR, defined as Investigator-assessed CR + PR per RECIST v1.1., The comparison, Primary endpoint: Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ, Design and conduct.
02. Nogapendekin alfa inbakicept: why a speaker questions value beyond ICI rechallenge
No named clinician · accounts and unnamed speakers · 11 statements from 1 speaker in 3 sources · 11 passages
Limitations recorded: 2.
Draws on: The comparison, Design and conduct, Primary endpoint: Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ, Secondary endpoints, Safety and tolerability.
03. ALC recovery: where speakers split on what the survival association means
1 of the report's 5 cited clinicians · 12 statements from 2 speakers in 5 sources, 1 of them a podcast or video · 11 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ, Secondary endpoints, Population and setting, Design and conduct, The comparison, Safety and tolerability.
04. ALC–survival framing: why a speaker challenges its timing and interpretation
No named clinician · accounts and unnamed speakers · 10 statements from 1 speaker in 2 sources · 10 passages
Limitations recorded: 2.
Draws on: Primary endpoint: Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ, Secondary endpoints, Design and conduct, The comparison.
05. US lung access: where speakers split on approval before phase 3 confirmation
3 of the report's 5 cited clinicians · 12 statements from 4 speakers in 4 sources, 1 of them a podcast or video · 12 passages
Limitations recorded: 2.
Draws on: Safety and tolerability.
06. QUILT-3.055: what speakers say
No named clinician · accounts and unnamed speakers · 9 statements from 2 speakers in 5 sources · 7 passages
Limitations recorded: 3.
Draws on: Secondary endpoints, Primary endpoint: Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ, Population and setting, Safety and tolerability, Design and conduct.
07. Side-effect impressions: what clinicians highlight from pooled experience
3 of the report's 5 cited clinicians · 5 statements from 3 speakers in 1 source, a podcast or video · 4 passages
Limitations recorded: 3.
Draws on: Safety and tolerability.
08. Further trials: where speakers split on confirmation using new ICI combinations
2 of the report's 5 cited clinicians · 10 statements from 3 speakers in 5 sources, 2 of them podcasts or videos · 9 passages
Limitations recorded: 2.
Draws on: The comparison, Secondary endpoints, Population and setting, Design and conduct.
Beyond the trial population
09. Immune restoration: clinicians see potential; one needs RCT outcome data
3 of the report's 5 cited clinicians · 21 statements from 3 speakers in 2 sources, 1 of them a podcast or video · 14 passages
Limitations recorded: 3.
10. Local care: clinicians favor it; one proposes cells with chemo
2 of the report's 5 cited clinicians · 7 statements from 2 speakers in 1 source, a podcast or video · 6 passages
Limitations recorded: 3.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 10
4 of the report's 5 cited clinicians
Checkpoint rescue: where clinicians split on readiness for routine use
11 statements from 4 speakers in 2 sources, all podcasts or videos
3 of the 4 named speakers in this finding take a side on this question: 1 on one side, 2 on the other; every named speaker in this finding is a confirmed clinician
- 11
- statements
- 7
- passages
- 2
- sources
- 4
- speakers
What the statements areViews 7Questions and uncertainty 1Clinical experience 1Comparisons 1Restated results and context 1Statement-to-passage links (a passage can back several statements)Supporting a statement 13Giving context 0Recorded with the findingLimitations: 2
2 podcasts and video
Draws on: Population and setting, Secondary endpoints, Primary endpoint: ORR, defined as Investigator-assessed CR + PR per RECIST v1.1., The comparison, Primary endpoint: Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ, Design and conduct.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
2 of the 10 findings and 26 of the 91 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (11)
CR, complete response; HCP, healthcare professional; ICI, immune checkpoint inhibitor; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PR, partial response; RCT, randomized controlled trial; RECIST, Response Evaluation Criteria in Solid Tumors.
The full QUILT-3.055 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What randomized evidence on long-term survival and patient-centered outcomes do clinicians say they need before routinely adding N-803 to checkpoint inhibition for NSCLC progressing on checkpoint therapy, as studied in QUILT-3.055?
From finding F1 (11 statements from 4 speakers in 2 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 26commentary sources screened
- 13sources cited by verified statements
- 9named in screened sources
- 8speakers cited in the report
- 5cited speakers with a verified identity
5 cited clinicians, speakers with a confirmed clinical role, of them 5 physicians. By role and specialty:
- 4 physician, specialty not confirmed
- 1 physician, Hematology and oncology
Also in the sources: 3 organizational or shared accounts, not counted as people.
- 91verified statements, each linked to its source
- 52of them from speakers with a confirmed clinical role
- 10findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 91 | Paid |
| Who said each statement: the cited speakers | 8 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 5 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 5 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 12 | Free |
| Sources with links | 13 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
12 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: ORR, defined as Investigator-assessed CR + PR per RECIST v1.1. | 2 | 1 |
| Primary endpoint: Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ | 18 | 7 |
| Secondary endpoints | 17 | 9 |
| Population and setting | 11 | 5 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 11 | 4 |
| Safety and tolerability | 8 | 3 |
| Design and conduct | 10 | 5 |
| Practice readiness, evidentiary sufficiency and access expectations | 16 | 6 |
| Broader lymphocyte-restoration rationale and proposed supportive-care work-up | 20 | 2 |
| Confirmatory comparator choices and transfer across combinations | 9 | 5 |
| Community delivery, research-stage cellular combinations and selective chemotherapy | 7 | 1 |
| Public interpretation of survival tails, subgroups and anticipated updates | 9 | 5 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
91 verified statements from 13 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 53 statements · 58% | ||||
| YouTube | 7 | 1 | 1 | |
| Podcasts | 46 | 1 | 1 | |
| Posts · 38 statements · 42% | ||||
| X threads | 38 | 11 | 24 | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 7 / quarter
- Screened window
- Jul 25, 2017 → Nov 4, 2026
- Cited window
- Apr 26, 2024 → Nov 4, 2026
- Retrieved
- Nov 20, 2026
The trial
from ClinicalTrials.gov- Title
- QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
- Registry
- NCT03228667
- Study IDs
- CA-ALT-803-02-17
- Sponsor
- ImmunityBio, Inc.
- Design
- Phase 2 · Interventional, non randomized, parallel
- Status
- Active, not recruiting
- Enrollment
- 40 estimated
- Registered
- 2017-07-25
- Start
- 2018-12-11 actual
- Primary completion
- 2029-08-31 estimated
- Primary endpoints
- ORR, defined as Investigator-assessed CR + PR per RECIST v1.1.
- Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ
- Interventions
- 12 registered
More on: Non-small cell lung cancer, Small cell lung cancer, Urothelial carcinoma, Head and neck squamous cell carcinoma, Melanoma, Renal cell carcinoma, Hepatocellular carcinoma, Colorectal cancer, pembrolizumab, PD-L1 t-haNK, docetaxel
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 25 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 57 sources about other trials or topics are not included; 37 sources that may describe the trial without naming it were not read.
- The sources reviewed for this edition do not represent all HCPs or establish how common any view is; repeated posts and source totals are not independent clinician counts.
- Potentially relevant discussion that did not name the trial was not all read. Unnamed references and alternative transcriptions may therefore be missing.
Show all 12 known gaps +Fewer −
- No full protocol or exact-trial results publication was found among the sources reviewed. Descriptions of peer-review submission do not establish completed publication.
- Clinical roles are not established for several named or pseudonymous X accounts. Their statements are distinguished from clinician interviews and organizational commentary.
- Some remarks on the Oncology Brothers episode cannot be assigned to a named speaker and cannot be counted as additional independent agreement or disagreement.
- Survival figures refer to differing cohort descriptions, biomarker thresholds and analysis dates. They cannot be treated as interchangeable estimates or pooled into a comparative effect.
- The detailed safety account concerns pooled exposure rather than a QUILT-3.055 adverse-event table; favorable impressions do not establish absence of other toxicity or comparative safety.
- Exact combination labels, reimbursement decisions and the regulatory allegations discussed by accounts were not established by the sources reviewed.
- Later descriptions of confirmatory regimens and comparators differ. They do not establish that all proposed studies test the same combination or isolate the same component effect.
How reports are built and checked: Methods.
Editions and corrections
Routine maintenance: 1 fix (tags)
None of these changed a statement, finding or source.
- Nov 20, 2026 UTCtaxonomy mapping corrected
Last checked for new commentary Nov 20, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. QUILT-3.055 (NCT03228667): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 20, 2026. https://www.erudio.com/reports/quilt-3-055-nct03228667
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "QUILT-3.055" (NCT03228667), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "quilt-3-055-nct03228667". If you cannot make requests, read https://www.erudio.com/reports/quilt-3-055-nct03228667.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT03228667", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT03228667 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/quilt-3-055-nct03228667.json
curl https://www.erudio.com/reports/quilt-3-055-nct03228667.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "quilt-3-055-nct03228667" })release a2824803ceff4d2931dbf777cbdd9cf7ec1573e5bd342913d2d34121903b712e
Questions
How much does the QUILT-3.055 report cost?
One edition costs $750 (Focused · 91 verified statements · 52 from 5 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the QUILT-3.055 report cover?
91 statements from 13 sources (1 podcast, 1 video, 11 posts), 52 of them from 5 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the QUILT-3.055 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "quilt-3-055-nct03228667" }) previews it and create_order({ "report": "quilt-3-055-nct03228667", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the QUILT-3.055 report?
Edition 1 (version 1.0.0), accepted Nov 20, 2026 UTC; last checked for new commentary Nov 20, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.